Ars Pharmaceuticals Inc (SPRY)

$17.18 -0.50 (-2.83%)
Market Cap 1.74B
Revenue (ttm) 89.15M
Net Income (ttm) 8.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 8.97%
Debt to Equity Ratio 0.30
Volume 1,181,300
Avg Vol 1,383,526
Day's Range N/A - N/A
Shares Out 98.21M
Stochastic %K 7%
Beta 0.90
Analysts Strong Sell
Price Target $32.00

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 771 9307
Address:
11682 El Camino Real, Suite 120, San Diego, United States
Cash_loot
Cash_loot Jul. 29 at 1:59 PM
$AQST Ahhhh just checking on the minions. Still in the 3's while $SPRY broke $18. Make sure you continue to listen to the Carnival barker, Maybe he'll give out more bagels at the next trade show.
1 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:33 PM
$SPRY Great piece that accurately captures SPRY's current position. So if you want to refresh your understanding of SPRY or learn about SPRY for the first time, this is essential reading. https://beyondspx.com/article/spry-unlocking-anaphylaxis-treatment-with-needle-free-innovation
0 · Reply
hbwalk2
hbwalk2 Jul. 28 at 5:39 PM
$SPRY People in the know seem to be sniffing out positive earnings, or perhaps some interest from Big Pharma. Getting VERY interesting
2 · Reply
hbwalk2
hbwalk2 Jul. 28 at 4:17 PM
$SPRY Wow! another 1000 contracts in the last 10 min
0 · Reply
hbwalk2
hbwalk2 Jul. 28 at 4:08 PM
$SPRY BiG Volume on Aug 20 calls. bullish
0 · Reply
clan
clan Jul. 26 at 3:25 AM
$MNKD $SPRY Might all these Neffy (needle-free, inhalable, pediatric-approved epinephrine spray) commercials be laying the groundwork for instilling in Mama Bears the safety of the also inhalable, needle-free mealtime insulin, Afrezza; soon to be approved for their kids. Imagine the Neffy commercial ... followed by the new Afrezza commercial showing kids inhaling their insulin. 🚫💉 #InhaleMyInsulin
1 · Reply
kitty_3
kitty_3 Jul. 24 at 2:10 PM
Its been getting rejected at 18 for weeks now. $SPRY
0 · Reply
Audiguyri
Audiguyri Jul. 23 at 12:19 AM
$SPRY anyone here?
1 · Reply
SouthHaus
SouthHaus Jul. 18 at 12:02 PM
$SPRY UK approves EURneffy for emergency use.
0 · Reply
JTMinor1
JTMinor1 Jul. 17 at 12:19 PM
$SPRY it’s looking pretty bright!!🎉🎉🚀🚀
1 · Reply
Latest News on SPRY
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Jul 18, 2025, 9:25 AM EDT - 15 days ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 2 months ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:32 PM EDT - 2 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 14, 2025, 7:00 AM EDT - 2 months ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 7, 2025, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

May 2, 2025, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ARS Pharmaceuticals Has A Blockbuster Candidate

Apr 30, 2025, 6:51 AM EDT - 3 months ago

ARS Pharmaceuticals Has A Blockbuster Candidate

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

Mar 20, 2025, 3:31 PM EDT - 4 months ago

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 1:28 PM EDT - 4 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 4 months ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 5, 2025, 4:10 PM EST - 5 months ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Mar 3, 2025, 4:35 PM EST - 5 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 20, 2025, 7:02 PM EST - 5 months ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 18, 2025, 8:00 AM EST - 5 months ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Feb 6, 2025, 1:04 AM EST - 6 months ago

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Jan 6, 2025, 8:00 AM EST - 7 months ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 19, 2024, 5:25 PM EST - 8 months ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 12, 2024, 2:32 PM EST - 8 months ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Dec 4, 2024, 8:00 AM EST - 8 months ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 12:40 PM EST - 9 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 6:30 AM EST - 9 months ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Nov 11, 2024, 7:41 AM EST - 9 months ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Nov 11, 2024, 7:00 AM EST - 9 months ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Nov 9, 2024, 5:30 PM EST - 9 months ago

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 9 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 9 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 30, 2024, 11:00 AM EDT - 9 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 24, 2024, 8:30 AM EDT - 10 months ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Oct 23, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 19, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 17, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

Oct 8, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

Oct 5, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Assist The Schall Law Firm

Oct 3, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Assist The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 1, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

Sep 29, 2024, 11:00 AM EDT - 10 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 28, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

Sep 27, 2024, 11:00 AM EDT - 11 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 24, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Should Contact The Schall Law Firm

Sep 23, 2024, 11:00 AM EDT - 11 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Should Contact The Schall Law Firm

The Schall Law Firm Urges Stockholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 20, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Urges Stockholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

Sep 19, 2024, 11:00 AM EDT - 11 months ago

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And The Schall Law Firm Wants Investors To Help With An Inquiry

Sep 17, 2024, 11:00 AM EDT - 11 months ago

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And The Schall Law Firm Wants Investors To Help With An Inquiry

Cash_loot
Cash_loot Jul. 29 at 1:59 PM
$AQST Ahhhh just checking on the minions. Still in the 3&#39;s while $SPRY broke $18. Make sure you continue to listen to the Carnival barker, Maybe he&#39;ll give out more bagels at the next trade show.
1 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:33 PM
$SPRY Great piece that accurately captures SPRY&#39;s current position. So if you want to refresh your understanding of SPRY or learn about SPRY for the first time, this is essential reading. https://beyondspx.com/article/spry-unlocking-anaphylaxis-treatment-with-needle-free-innovation
0 · Reply
hbwalk2
hbwalk2 Jul. 28 at 5:39 PM
$SPRY People in the know seem to be sniffing out positive earnings, or perhaps some interest from Big Pharma. Getting VERY interesting
2 · Reply
hbwalk2
hbwalk2 Jul. 28 at 4:17 PM
$SPRY Wow! another 1000 contracts in the last 10 min
0 · Reply
hbwalk2
hbwalk2 Jul. 28 at 4:08 PM
$SPRY BiG Volume on Aug 20 calls. bullish
0 · Reply
clan
clan Jul. 26 at 3:25 AM
$MNKD $SPRY Might all these Neffy (needle-free, inhalable, pediatric-approved epinephrine spray) commercials be laying the groundwork for instilling in Mama Bears the safety of the also inhalable, needle-free mealtime insulin, Afrezza; soon to be approved for their kids. Imagine the Neffy commercial ... followed by the new Afrezza commercial showing kids inhaling their insulin. 🚫💉 #InhaleMyInsulin
1 · Reply
kitty_3
kitty_3 Jul. 24 at 2:10 PM
Its been getting rejected at 18 for weeks now. $SPRY
0 · Reply
Audiguyri
Audiguyri Jul. 23 at 12:19 AM
$SPRY anyone here?
1 · Reply
SouthHaus
SouthHaus Jul. 18 at 12:02 PM
$SPRY UK approves EURneffy for emergency use.
0 · Reply
JTMinor1
JTMinor1 Jul. 17 at 12:19 PM
$SPRY it’s looking pretty bright!!🎉🎉🚀🚀
1 · Reply
andras1
andras1 Jul. 14 at 5:25 PM
$SPRY EURneffy/neffy emerging as serious EpiPen alternative—and the data keeps coming https://www.thepharmaletter.com/pharmaceutical/eurneffy-neffy-emerging-as-serious-epipen-alternative-and-the-data-keeps-coming
1 · Reply
JTMinor1
JTMinor1 Jul. 14 at 10:53 AM
$SPRY really?
1 · Reply
JTMinor1
JTMinor1 Jul. 11 at 7:33 PM
$SPRY shorts are really brave or really stupid
0 · Reply
hbwalk2
hbwalk2 Jul. 11 at 6:09 PM
$SPRY looking like she wants to blow higher, especially with that green hammer yesterday
1 · Reply
SqueezeFinder1
SqueezeFinder1 Jul. 8 at 1:16 PM
Good morning, SqueezeFinders! 4. $SPRY Squeezability Score: 53% Juice Target: 56.9 Confidence: 🍊 🍊 Price: 17.09 (+3.45%) Breakdown point: 16.9 Breakout point: 18.9 Mentions (30D): 8 Event/Condition: Massive rel vol spike on strong earnings report + shaping up to be an inverse H&amp;S technical pattern playing out on the daily time-frame + Recent price target 🎯 of $32 from Raymond James 5. $PCT Squeezability Score: 53% Juice Target: 28.9 Confidence: 🍊 🍊 🍊 Price: 14.53 (+5.6%) Breakdown point: 11.0 Breakout point: 15.6 Mentions (30D): 1 Event/Condition: Potentially imminent multi-year rangebound consolidation breakout + Huge rel vol spike after company announces they are raising $300M to fund global expansion + Recent price target 🎯 of $15 from Alembic Global + Potentially imminent massive cup &amp; handle technical pattern underway. To gain access to all our cutting-edge research tools, live watchlists, alerts, and more: http://www.squeeze-finder.com/subscribe
0 · Reply
JTMinor1
JTMinor1 Jul. 8 at 11:34 AM
$EBS not lookin as squeezy as $SPRY
0 · Reply
JTMinor1
JTMinor1 Jul. 7 at 4:16 PM
$SPRY Things are feeling a bit squeezy here!
1 · Reply
Paddy444
Paddy444 Jul. 3 at 1:09 AM
$SPRY Temporary thoughts- what the fk, oh my God its way down today, everyone must know something, dilution, etc etc Paddy- see ya well past 20.00 soon, I can&#39;t stop them, I just can&#39;t or Watch cable and see the commercials- you know what the whatevers do with these commercials- Who cares but it certainly makes the stock go up for those said people. After diligence, learn the ways Later
0 · Reply
Ravery
Ravery Jul. 2 at 5:02 PM
$AQST $SPRY Deerfield joining the exit party from SPRY shares. https://www.secform4.com/filings/1671858/0001193805-25-000959.htm
2 · Reply
YaBoyJ313
YaBoyJ313 Jul. 2 at 4:56 PM
$AQST management MUST secure a partnership or BO! Period! If they do not, there will 100% be a future dilution to raise capital. Cash runway was ~$60M and could sustain through PDUFA, but is not enough to support salesforce, marketing, and manufacturing costs necessary to float company until revenue generated from Anaphylm. $SPRY secured a great partner and secured $450M, all while having a larger cash runway than $AQST. I&#39;m not being negative, just being realistic here. I still believe in my original $17 PT, I just need to see follow through from management and share price needs to eventually reflect proper valuation, otherwise wtf is even going on...
4 · Reply
prototyper
prototyper Jul. 1 at 5:01 PM
$SPRY waiting for 12-13
1 · Reply
Quantumup
Quantumup Jun. 30 at 8:18 PM
Raymond James reiterated $SPRY Strong Buy-$32 and said &quot;As a result of heavy investor interest in our neffy script analysis note, we caught up with management to get additional detail on the key dynamics impacting the 2Q number and beyond.&quot; $AQST $TEVA $UNH Raymond James went on to say:
1 · Reply